Cargando…

Association between PPAR-γ2 gene polymorphisms and diabetic retinopathy risk: a meta-analysis

A close association between peroxisome proliferator-activated receptor-γ2 (PPAR-γ2) and the development of diabetic retinopathy (DR) has been previously suggested. Herein, a meta-analysis was conducted to explore the association between PPAR-γ2 polymorphisms and DR risk by performing a systematic se...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Xue-Feng, Jiang, Guang-Bin, Cheng, Shi-Yan, Song, Ya-Feng, Deng, Cai, Niu, Yu-Ming, Cai, Jun-Wei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals 2021
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7950267/ https://www.ncbi.nlm.nih.gov/pubmed/33535175 http://dx.doi.org/10.18632/aging.202433

Ejemplares similares

PPARγ Agonists: Potential as Therapeutics for Neovascular Retinopathies
por: Pershadsingh, Harrihar A., et al.
Publicado: (2008)

Protopanaxatriol, a novel PPARγ antagonist from Panax ginseng, alleviates steatosis in mice
por: Zhang, Yu, et al.
Publicado: (2014)

PPAR α and PPAR γ Polymorphisms as risk factors for Dyslipidemia in a Chinese han population
por: Gu, Shu-Jun, et al.
Publicado: (2014)

Relationship between PPAR‐γ gene polymorphisms and ischemic stroke risk: A meta‐analysis
por: Cheng, Fan, et al.
Publicado: (2021)

PPARγ Gene Polymorphisms, Metabolic Disorders, and Coronary Artery Disease
por: Song, Yongyan, et al.
Publicado: (2022)

The association between the PPARγ2 Pro12Ala polymorphism and nephropathy susceptibility in type 2 diabetes: a meta-analysis based on 9,176 subjects
por: Wang, Lei, et al.
Publicado: (2013)

Haplotype Analysis of PPARγ Gene Polymorphisms and the Lipoprotein (a) Level
por: SHEN, Chao, et al.
Publicado: (2018)

Dietary component isorhamnetin is a PPARγ antagonist and ameliorates metabolic disorders induced by diet or leptin deficiency
por: Zhang, Yu, et al.
Publicado: (2016)

Neuroprotective effects of PPARα in retinopathy of type 1 diabetes
por: Pearsall, Elizabeth A., et al.
Publicado: (2019)

MDG-1, a Potential Regulator of PPARα and PPARγ, Ameliorates Dyslipidemia in Mice
por: Wang, Xu, et al.
Publicado: (2017)

PPARα Agonist Oral Therapy in Diabetic Retinopathy
por: Tomita, Yohei, et al.
Publicado: (2020)

Meta-Analysis on the Association of ALDH2 Polymorphisms and Type 2 Diabetic Mellitus, Diabetic Retinopathy
por: Li, Guang-Yi, et al.
Publicado: (2017)

PPARγ and Apoptosis in Cancer
por: Elrod, Heath A., et al.
Publicado: (2008)

Serum PPARγ level and PPARγ gene polymorphism as well as severity and prognosis of brain injury in patients with arteriosclotic cerebral infarction
por: Wei, Weiming, et al.
Publicado: (2018)

Caspase-1 cleaves PPARγ for potentiating the pro-tumor action of TAMs
por: Niu, Zhiyuan, et al.
Publicado: (2017)

Association between the pri-miR-26a-1 rs7372209 C>T polymorphism and cancer susceptibility: multivariate analysis and trial sequential analysis
por: Hu, Yuan-Yuan, et al.
Publicado: (2020)

PPARγ2(Pro12Ala) Polymorphism and Human Health
por: He, Weimin
Publicado: (2009)

Neobavaisoflavone Induces Bilirubin Metabolizing Enzyme UGT1A1 via PPARα and PPARγ
por: Zhu, Ya-Di, et al.
Publicado: (2021)

The case for intraocular delivery of PPAR agonists in the treatment of diabetic retinopathy
por: Treacy, Maxwell P, et al.
Publicado: (2012)

PPARγ in Neuroblastoma
por: Peri, Alessandro, et al.
Publicado: (2008)

Obesity-linked phosphorylation of PPARγ by cdk5 is a direct target of the anti-diabetic PPARγ ligands
por: Choi, Jang Hyun, et al.
Publicado: (2010)

Association Between Vitamin D Receptor Gene Polymorphisms and Polycystic Ovary Syndrome Risk: A Meta-Analysis
por: Niu, Yu-Ming, et al.
Publicado: (2019)

Emerging PPARγ-Independent Role of PPARγ Ligands in Lung Diseases
por: Kulkarni, Ajit A., et al.
Publicado: (2012)

Therapeutic Implications of PPARγ in Human Osteosarcoma
por: Wagner, Eric R., et al.
Publicado: (2010)

KLF13 promotes porcine adipocyte differentiation through PPARγ activation
por: Jiang, Shuzhong, et al.
Publicado: (2015)

The C1431T polymorphism of peroxisome proliferator activated receptor γ (PPARγ) is associated with low risk of diabetes in a Pakistani cohort
por: Butt, Huma, et al.
Publicado: (2016)

The Potential Roles of Post-Translational Modifications of PPARγ in Treating Diabetes
por: Ji, Xiaohui, et al.
Publicado: (2022)

Scaffold-Based Pan-Agonist Design for the PPARα, PPARβ and PPARγ Receptors
por: Zhang, Li-Song, et al.
Publicado: (2012)

Risk factors and prevalence of diabetic retinopathy: A protocol for meta-analysis
por: Hou, Yuying, et al.
Publicado: (2020)

Baicalin Promotes CNS Remyelination via PPARγ Signal Pathway
por: Ai, Ruo-Song, et al.
Publicado: (2022)

The Role of PPARγ Gene Polymorphisms, Gut Microbiota in Type 2 Diabetes: Current Progress and Future Prospects
por: Zhao, Yi-Kun, et al.
Publicado: (2023)

Traditional chinese medicine for diabetic retinopathy: A systematic review and meta-analysis
por: Pang, Bing, et al.
Publicado: (2020)

PPARγ, neuroinflammation, and disease
por: Mrak, Robert E, et al.
Publicado: (2004)

Nutraceuticals as Ligands of PPARγ
por: Penumetcha, Meera, et al.
Publicado: (2012)

PPARγ and Cognitive Performance
por: d’Angelo, Michele, et al.
Publicado: (2019)

New Insights into the PPARγ Agonists for the Treatment of Diabetic Nephropathy
por: Jia, Zhanjun, et al.
Publicado: (2014)

Impact of Targeted PPARγ Disruption on Bone Remodeling
por: Cao, Jay, et al.
Publicado: (2015)

Phosphorylation of PPARγ Affects the Collective Motions of the PPARγ-RXRα-DNA Complex
por: Lemkul, Justin A., et al.
Publicado: (2015)

Ups and downs: The PPARγ/p-PPARγ seesaw of follistatin-like 1 and integrin receptor signaling in adipogenesis
por: Fang, Dongliang, et al.
Publicado: (2021)

Therapeutic Effects of PPARα Agonists on Diabetic Retinopathy in Type 1 Diabetes Models
por: Chen, Ying, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_d2lhsmd2ph5e786uo9ieiaf6ua